GLMD vs. FWBI, CYCN, TRVN, ASLN, LGVN, HEPA, BNOX, PULM, TENX, and ENTO
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include First Wave BioPharma (FWBI), Cyclerion Therapeutics (CYCN), Trevena (TRVN), ASLAN Pharmaceuticals (ASLN), Longeveron (LGVN), Hepion Pharmaceuticals (HEPA), Bionomics (BNOX), Pulmatrix (PULM), Tenax Therapeutics (TENX), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical preparations" industry.
First Wave BioPharma (NASDAQ:FWBI) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
First Wave BioPharma presently has a consensus target price of $36.00, indicating a potential upside of ∞. Given Galmed Pharmaceuticals' higher probable upside, analysts clearly believe First Wave BioPharma is more favorable than Galmed Pharmaceuticals.
12.3% of First Wave BioPharma shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.5% of First Wave BioPharma shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
First Wave BioPharma has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Galmed Pharmaceuticals received 432 more outperform votes than First Wave BioPharma when rated by MarketBeat users. Likewise, 65.29% of users gave Galmed Pharmaceuticals an outperform vote while only 45.45% of users gave First Wave BioPharma an outperform vote.
In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than First Wave BioPharma. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for First Wave BioPharma. Galmed Pharmaceuticals' average media sentiment score of 1.87 beat First Wave BioPharma's score of 0.72 indicating that First Wave BioPharma is being referred to more favorably in the media.
First Wave BioPharma's return on equity of -53.29% beat Galmed Pharmaceuticals' return on equity.
Summary
Galmed Pharmaceuticals beats First Wave BioPharma on 8 of the 12 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
